These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32953160)

  • 21. Cholangiocarcinoma: the quest for a second-line systemic treatment.
    Vienot A; Neuzillet C
    Transl Cancer Res; 2019 Apr; 8(Suppl 3):S275-S288. PubMed ID: 35117107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuum of care for advanced biliary tract cancers.
    Vienot A; Neuzillet C
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):810-824. PubMed ID: 32586782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimum chemotherapy for the management of advanced biliary tract cancer.
    Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
    World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study.
    Kato A; Shimizu H; Ohtsuka M; Yoshidome H; Yoshitomi H; Furukawa K; Takeuchi D; Takayashiki T; Kimura F; Miyazaki M
    Ann Surg Oncol; 2013 Jan; 20(1):318-24. PubMed ID: 23149849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer.
    Mirallas O; López-Valbuena D; García-Illescas D; Fabregat-Franco C; Verdaguer H; Tabernero J; Macarulla T
    ESMO Open; 2022 Jun; 7(3):100503. PubMed ID: 35696747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination Therapies for Advanced Biliary Tract Cancer.
    Zeng W; Mao R; Zhang Z; Chen X
    J Clin Transl Hepatol; 2023 Apr; 11(2):490-501. PubMed ID: 36643047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer.
    Yonemoto N; Furuse J; Okusaka T; Yamao K; Funakoshi A; Ohkawa S; Boku N; Tanaka K; Nagase M; Saisho H; Sato T
    Jpn J Clin Oncol; 2007 Nov; 37(11):843-51. PubMed ID: 17942578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating soft tissue sarcomas with adjuvant chemotherapy.
    Patrikidou A; Domont J; Cioffi A; Le Cesne A
    Curr Treat Options Oncol; 2011 Mar; 12(1):21-31. PubMed ID: 21384115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chemotherapy for Biliary Tract Cancer].
    Woo SM
    Korean J Gastroenterol; 2017 Mar; 69(3):172-176. PubMed ID: 28329919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.
    Filippi R; Lombardi P; Quarà V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M
    Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186
    [No Abstract]   [Full Text] [Related]  

  • 31. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.
    Sun W; Patel A; Normolle D; Patel K; Ohr J; Lee JJ; Bahary N; Chu E; Streeter N; Drummond S
    Cancer; 2019 Mar; 125(6):902-909. PubMed ID: 30561756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience.
    Wu CE; Chou WC; Hsieh CH; Chang JW; Lin CY; Yeh CN; Chen JS
    BMC Cancer; 2020 May; 20(1):422. PubMed ID: 32410631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of second‑line chemotherapy after gemcitabine and cisplatin plus S‑1 treatment for patients with advanced biliary tract cancer in the KHBO1401‑3A study.
    Shindo Y; Nagano H; Kanai M; Kobayashi S; Wada H; Sakai D; Eguchi H; Baba H; Kamachi H; Takayama T; Ueno M; Takahashi M; Nakagami Y; Yoshimura K; Hatano E; Ioka T
    Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36633148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
    Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
    BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes in older patients with biliary tract cancer.
    McNamara MG; de Liguori Carino N; Kapacee ZA; Lamarca A; Valle JW
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt A):569-575. PubMed ID: 32209312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
    Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
    Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic therapy for biliary tract cancers.
    Hezel AF; Zhu AX
    Oncologist; 2008 Apr; 13(4):415-23. PubMed ID: 18448556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognosis related to treatment plan in patients with biliary tract cancer: A nationwide database study.
    Renteria Ramirez DE; Knøfler LA; Kirkegård J; Fristrup CW; Stender MT; Nielsen SD; Markussen A; Larsen PN; Akdag D; Al-Saffar HA; Pommergaard HC
    Cancer Epidemiol; 2024 Dec; 93():102688. PubMed ID: 39418943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.
    Yokoyama T; Yoshida H; Makino H; Maruyama H; Suzuki S; Matsutani T; Matsushita A; Hirakata A; Sasajima K; Uchida E
    J Nippon Med Sch; 2012; 79(3):204-12. PubMed ID: 22791122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety.
    Khankhel ZS; Goring S; Bobiak S; Lamy FX; Nayak D; Garside J; Reese ES; Schoenherr N
    Future Oncol; 2022 Jun; 18(18):2321-2338. PubMed ID: 35387496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.